The UK’s medicines regulator on Thursday approved an antibody treatment for COVID-19, the disease caused by the CCP virus. Xevudy (sotrovimab), developed by GlaxoSmithKline (GSK) and Vir Biotechnology, is the second monoclonal antibody treatment approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) after it approved Lagevrio (molnupiravir) last month. The drug is administered by intravenous infusion over 30 minutes, and it is approved for people aged 12 and over and weighing more than 40 kg (88 pounds). It’s authorised for use in people who have mild to moderate CCP (Chinese Communist Party) virus infection and at least one risk factor for developing severe illness, such as obesity, older age (55 years and over), diabetes mellitus, or heart disease. MHRA said one dose of the single monoclonal antibody was found in a clinical trial to reduce the risk of hospitalisation and death by 79 percent in high-risk adults with symptomatic CCP virus infection. The agency recommended …